On May 7, 2023, a delegation led by Dr. Wang Yue, Chairman of the Cell and Gene Therapy Product Regulation Research Committee under the China Society for Drug Regulation (hereinafter referred to as the "Committee"), visited Shenzhen Eureka Biotechnology Co., Limited (hereinafter referred to as "EurekaBio") in Shenzhen for research and guidance purposes. The delegation comprised of esteemed members, including Wang Bing, President of Shenzhen Institute for Drug Control (hereinafter referred to as “SIDC”), Wang Ping, Vice-President of SIDC, and Qin Meirong, Director of SIDC Pharmacology and Toxicology Department.

During the symposium, Ma Mo delivered an insightful presentation, delving into EurekaBio's pioneering technological advancements and innovative breakthroughs in the field of CGT. He provided detailed insights into the therapeutic mechanisms and production processes associated with cell and gene therapies. Additionally, he introduced the company's cutting-edge R&D endeavors, including the EuLV® system, which utilizes stable cell producer lines for large-scale production of lentiviral vectors, and the proprietary CellSep® automated cell processing system. The presentation effectively demonstrated EurekaBio's robust platform infrastructure, strategic industry positioning, remarkable research accomplishments, and outstanding service track record.

Following the presentation, the two parties engaged in fruitful discussions regarding the regulation of CGT products, scientific research innovation, and industrial development. The objective was to devise effective strategies and provide valuable guidance to enhance the quality, safety, technological advancements, and production efficiency within the CGT industry.
Dr. Wang Yue expressed sincere appreciation and profound recognition for EurekaBio's product novelty, technological foresight, and establishment of a robust platform. He highly anticipated EurekaBio's proactive engagement in diverse research endeavors and innovative practices, with the objective of delivering superior products, technologies, and services to the industry.
Ma Mo affirmed that EurekaBio will remain steadfast in upholding its mission of "Empowering CGT and Confronting the Toughest Challenges in the Industry", persistently harnessing its inherent strengths and dynamic capabilities to drive multifaceted industry expansion. ”
During the conclusion of the symposium, Dr. Wang Yue delivered his closing statements, extending heartfelt gratitude towards EurekaBio and the SIDC for their warm-hearted reception. Dr. Wang Yue emphasized the importance of high-quality development in the CGT industry and highlighted the need for collaborative exploration among professionals from various fields. He urged enterprises to strengthen communication and cooperation with regulatory bodies, actively participate in the formulation of industry standards, and collectively contribute to the sustainable growth of the industry.

The Committee members and leaders from the SIDC also visited EurekaBio's exhibition hall and production research laboratory. They conducted a thorough exploration of the company's core equipment, pioneering technologies, and robust quality management system. Inspired by their profound observations, they expressed optimism for the company's future development. 
Seizing this valuable opportunity, EurekaBio will harness its profound expertise within the CGT industry to continuously pursue process optimization, foster technological breakthroughs, and elevate quality standards. Through collaborative research and active engagement with industry counterparts across the supply chain, the company remains dedicated to enhancing the uniformity of CGT product quality and ensuring greater accessibility to medications. By doing so, EurekaBio aims to profoundly enrich the lives of patients.